Allan Haldane

Allan Haldane

Auto-generated profile, based on publicly available information

Allan Haldane

Temple University

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 November 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
FMFrancisco McGee
Francisco McGee
SHSandro Hauri
Sandro Hauri
QNQuentin Novinger
Quentin Novinger
SVSlobodan Vucetic
Slobodan Vucetic
RLRonald M. Levy
Ronald M. Levy
AHAllan Haldane
Allan Haldane
Potts models and variational autoencoders (VAEs) have recently gained popularity as generative protein sequence models (GPSMs) to explore fitness landscapes and predict mutation effects. Despite encouraging results, current model evaluation metrics leave unclear whether GPSMs faithfully reproduce the complex multi-residue mutational patterns observed in natural sequences due to epistasis. Here, we develop a set of sequence statistics to assess the “generative capacity” of three current GPSMs: the pairwise Potts Hamiltonian, the VAE, and the site-independent model. We show that the Potts model’s generative capacity is largest, as the higher-order mutational statistics generated by the model agree with those observed for natural sequences, while the VAE’s lies between the Potts and site-independent models. Importantly, our work provides a new framework for evaluating and interpreting GPSM accuracy which emphasizes the role of higher-order covariation and epistasis, with broader implications for probabilistic sequence models in general.

8 October 2019 in eLife
Verified
Journal Article
Open access
BABiswas Avik
Biswas Avik
AHAllan Haldane
Allan Haldane
EAEddy Arnold
Eddy Arnold
RLRonald M. Levy
Ronald M. Levy
The development of drug resistance in HIV is the result of primary mutations whose effects on viral fitness depend on the entire genetic background, a phenomenon called ‘epistasis’. Based on protein sequences derived from drug-experienced patients in the Stanford HIV database, we use a co-evolutionary (Potts) Hamiltonian model to provide direct confirmation of epistasis involving many simultaneous mutations. Building on earlier work, we show that primary mutations leading to drug resistance can become highly favored (or entrenched) by the complex mutation patterns arising in response to drug therapy despite being disfavored in the wild-type background, and provide the first confirmation of entrenchment for all three drug-target proteins: protease, reverse transcriptase, and integrase; a comparative analysis reveals that NNRTI-induced mutations behave differently from the others. We further show that the likelihood of resistance mutations can vary widely in patient populations, and from the population average compared to specific molecular clones.

21 July 2023 in Science Advances
Verified
Journal Article
Open access
MLMin Li
Min Li
DPDario Oliveira Passos
Dario Oliveira Passos
ZSZelin Shan
Zelin Shan
SSsteve smith
steve smith
QSQinfang Sun
Qinfang Sun
DLDmitry Lyumkis
Dmitry Lyumkis
HIV-1 infection depends on the integration of viral DNA into host chromatin. Integration is mediated by the viral enzyme integrase and is blocked by integrase strand transfer inhibitors (INSTIs), first-line antiretroviral therapeutics widely used in the clinic. Resistance to even the best INSTIs is a problem, and the mechanisms of resistance are poorly understood. Here, we analyze combinations of the mutations E138K, G140A/S, and Q148H/K/R, which confer resistance to INSTIs. The investigational drug 4d more effectively inhibited the mutants compared with the approved drug Dolutegravir (DTG). We present 11 new cryo-EM structures of drug-resistant HIV-1 intasomes bound to DTG or 4d, with better than 3-Å resolution. These structures, complemented with free energy simulations, virology, and enzymology, explain the mechanisms of DTG resistance involving E138K + G140A/S + Q148H/K/R and show why 4d maintains potency better than DTG. These data establish a foundation for further development of INSTIs that potently inhibit resistant forms in integrase.

5 March 2019 in Physical Review E
Verified
Journal Article
Closed access
PDF file
AHAllan Haldane
Allan Haldane
RLRonald M. Levy
Ronald M. Levy
Potts statistical models have become a popular and promising way to analyze mutational covariation in protein multiple sequence alignments (MSAs) in order to understand protein structure, function, and fitness. But the statistical limitations of these models, which can have millions of parameters and are fit to MSAs of only thousands or hundreds of effective sequences using a procedure known as inverse Ising inference, are incompletely understood. In this work we predict how model quality degrades as a function of the number of sequences N, sequence length L, amino-acid alphabet size q, and the degree of conservation of the MSA, in different applications of the Potts models: in “fitness” predictions of individual protein sequences, in predictions of the effects of single-point mutations, in “double mutant cycle” predictions of epistasis, and in 3D contact prediction in protein structure. We show how as MSA depth N decreases an “overfitting” effect occurs such that sequences in the training MSA have overestimated fitness, and we predict the magnitude of this effect and discuss how regularization can help correct for it, using a regularization procedure motivated by statistical analysis of the effects of finite sampling. We find that as N decreases the quality of point-mutation effect predictions degrade least, fitness and epistasis predictions degrade more rapidly, and contact predictions are most affected. However, overfitting becomes negligible for MSA depths of more than a few thousand effective sequences, as often used in practice, and regularization becomes less necessary. We discuss the implications of these results for users of Potts covariation analysis.

23 December 2022 in eLife
Verified
Journal Article
Open access
JGJoan Gizzio
Joan Gizzio
ATAbhishek Thakur
Abhishek Thakur
AHAllan Haldane
Allan Haldane
RLRonald M. Levy
Ronald M. Levy
Inactive conformations of protein kinase catalytic domains where the DFG motif has a “DFG-out” orientation and the activation loop is folded present a druggable binding pocket that is targeted by FDA-approved ‘type-II inhibitors’ in the treatment of cancers. Tyrosine kinases (TKs) typically show strong binding affinity with a wide spectrum of type-II inhibitors while serine/threonine kinases (STKs) usually bind more weakly which we suggest here is due to differences in the folded to extended conformational equilibrium of the activation loop between TKs vs. STKs. To investigate this, we use sequence covariation analysis with a Potts Hamiltonian statistical energy model to guide absolute binding free-energy molecular dynamics simulations of 74 protein-ligand complexes. Using the calculated binding free energies together with experimental values, we estimated free-energy costs for the large-scale (~17–20 Å) conformational change of the activation loop by an indirect approach, circumventing the very challenging problem of simulating the conformational change directly. We also used the Potts statistical potential to thread large sequence ensembles over active and inactive kinase states. The structure-based and sequence-based analyses are consistent; together they suggest TKs evolved to have free-energy penalties for the classical ‘folded activation loop’ DFG-out conformation relative to the active conformation, that is, on average, 4–6 kcal/mol smaller than the corresponding values for STKs. Potts statistical energy analysis suggests a molecular basis for this observation, wherein the activation loops of TKs are more weakly ‘anchored’ against the catalytic loop motif in the active conformation and form more stable substrate-mimicking interactions in the inactive conformation. These results provide insights into the molecular basis for the divergent functional properties of TKs and STKs, and have pharmacological implications for the target selectivity of type-II inhibitors.

1 March 2021 in Computer Physics Communications
Verified
Journal Article
Closed access
AHAllan Haldane
Allan Haldane
RLRonald M. Levy
Ronald M. Levy